Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MST1R | Q04912 | 5/20 | 0.60 |
| ▸ | AXL | P30530 | 11/20 | 0.59 |
| ▸ | MET | P08581 | 10/20 | 0.59 |
| ▸ | KDR | P35968 | 8/20 | 0.59 |
| ▸ | FLT3 | P36888 | 3/20 | 0.59 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.59 |
| ▸ | KIT | P10721 | 2/20 | 0.59 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.59 |
| ▸ | MERTK | Q12866 | 4/20 | 0.45 |
| ▸ | ABL1 | P00519 | 2/20 | 0.45 |
| ▸ | LCK | P06239 | 2/20 | 0.45 |
| ▸ | LYN | P07948 | 2/20 | 0.45 |
| ▸ | HCK | P08631 | 2/20 | 0.45 |
| ▸ | BCR | P11274 | 2/20 | 0.45 |
| ▸ | SRC | P12931 | 2/20 | 0.45 |
| ▸ | ABL2 | P42684 | 2/20 | 0.45 |
| ▸ | FRK | P42685 | 2/20 | 0.45 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.45 |
| ▸ | PTK6 | Q13882 | 2/20 | 0.45 |
| ▸ | DDR2 | Q16832 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL104767 | 0.92 | AXL (0.62) | MST1RAXLMETKDRFLT3 | |
| SCHEMBL169838 | 0.91 | MET (0.72) | MST1RAXLMETKDRFLT3 | |
| SCHEMBL29998555 | 0.91 | MET (0.72) | MST1RAXLMETKDRFLT3 | |
| SCHEMBL19026748 | 0.89 | MET (0.65) | MST1RAXLMETKDRFLT3 | |
| SCHEMBL169907 | 0.86 | KDR (0.58) | MST1RAXLMETKDRFLT3 | |
| SCHEMBL23118270 | 0.86 | MST1R (0.68) | MST1RAXLMETKDRFLT3 | |
| SCHEMBL2537860 | 0.85 | MET (0.72) | MST1RAXLMETKDRFLT3 | |
| SCHEMBL10172980 | 0.85 | AXL (0.81) | MST1RAXLMETKDRFLT3 | |
| SCHEMBL16660507 | 0.83 | MET (0.56) | MST1RAXLMETKDRFLT3 | |
| SCHEMBL171868 | 0.83 | MST1R (0.57) | MST1RAXLMETKDRFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9018378-B2 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | METHYLGENE INC. (CA) | 2015-04-28 | — | — | US | disclosed |
| US-8907091-B2 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | METHYLGENE INC. (CA) | 2014-12-09 | — | — | US | disclosed |
| US-20090286984-A1 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | Mirati Therapeutics, Inc. | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286984-A1 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | MAP3K19, MAP3K9, MAP4K2 | MST1R 759/4885AXL 418/4885MET 1062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.